Pfizer Reports Five-Year BFORE Data for Bosulif in Chronic Myeloid Leukemia

Pfizer today presented five-year follow-up data from the Phase 3 BFORE trial evaluating Bosulif (bosutinib) versus imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. The data showed that Bosulif maintained significantly higher rates of major molecular response at five years compared to imatinib, with 47.2% versus 36.9% of patients achieving MMR.